News from ODYSSEY OUTCOMES: Effects of PCSK9 inhibition on total cardiovascular disease burden New US Cholesterol Guidelines: The good, the bad and the ugly Prof. Gilles Montalescot – Key questions A target level for LDL-C in secondary prevention: What have we learned from PCSK9 inhibitor trials?LDL subclasses, bioactive lipids and atherogenicity: Impact of statin action COVID-19 infection and cardiovascular events ODYSSEY OUTCOMES Economics Study: How can we get the best value from PCSK9 inhibitors?Alirocumab safe in patients with diabetes mellitus

About the PCSK9 Education and Research Forum

PCSK9 Education and Research Forum is the independent resource on PCSK9 science and its translation into critically important new treatments to lower low density lipoprotein cholesterol (LDL-C), which promise to transform the prognosis of millions of patients with hypercholesterolaemia (cholesterol disorders), accelerated atherosclerotic vascular heart disease and a high risk of premature cardiovascular (CV) death and disability.
Aims & Objectives Mission Statement Editorial Board Partnership & Outreach Forthcoming Meetings

Download Now: New Slide Deck Programme

Previous slide decks focused on landmark studies which used a monoclonal antibody approach to inhibit PCSK9. The next in this series discusses inclisiran, a small interfering RNA therapy, which prevents production of PCSK9 at its primary source in the liver.

Find out more »

Download NowUNIQUE FREE APPAdvances in lipid lowering - a clinical guide

Virtual meeting

October 4-7, 2020

New data from ELIPSE HoFH with evinacumab
LIB003: 52-week data
News from ORION-11, ORION-9 with inclisiran

ESC Congress 2020
The Digital Experience

29 August – 1 September

HAUSER-RCT: Evolocumab in paediatric heterozygous FH
HAUSER-RCT: Expert viewpoint; latest videos
DA-VINCI: LDL management in Europe

Most viewed

A target level for LDL-C in secondary prevention: What have we learned from PCSK9 inhibitor trials? Cost-effectiveness of PCSK9 inhibitors: A coming of age? HPS-4/TIMI 65 ORION-4 Why we need PCSK9 inhibitors: goal attainment too low with statin plus ezetimibe VIDEO: PCSK9 Forum Editor Professor John Chapman gives his take home messages about lipoprotein(a) ORION-10 VIDEO: New insights from ODYSSEY OUTCOMES ALN-PCSsc, first-in-class PCSK9 RNA interference therapeutic advances to Phase II ORION-11 VIDEO: Perspective on the ODYSSEY OUTCOMES Economic Study

Most viewed

A target level for LDL-C in secondary prevention: What have we learned from PCSK9 inhibitor trials?

Hot Topics

13th Closed Virtual Meeting of the Editorial Board of PCSK9 Forum

Targets for LDL cholesterol: What have we learned from the trials?

Prof. Greg G. Schwartz discusses evidence from ODYSSEY OUTCOMES which supports the LDL cholesterol targets recommended for very high-risk patients by the 2019 ESC/EAS lipid guidelines.
Watch the webcast

Cost-effectiveness of PCSK9 inhibitors: A coming of age?

Dr. Kirsten Bibbins-Domingo and Prof. Dhruv S. Kazi discuss how cost-effectiveness analyses guided pricing for PCSK9 monoclonal antibodies in the USA. Initial high prices were counterproductive to uptake: will the situation be different for inclisiran?
Watch the webcast

From the Editors

Paediatric familial hypercholesterolaemia attracts new focus

Dr Albert Wiegman, Amsterdam University Medical Center, The Netherlands discusses the latest findings that have highlighted familial hypercholesterolaemia in children.

Read the report

Other related reports:

Professor Santos discusses HAUSER-RCT
Watch the video

Safety of LDL lowering in FH children
Read the report

EAS Consensus Panel on paediatric FH
Watch the video